INTRODUCTION Acute B-lymphoblastic leukemia (B-ALL) is a prevalent B-cell malignancy that often expresses the CD19 antigen, affecting all age groups. While CD19-targeted CAR-T cell therapy has shown remarkable
Tonn, T. et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 15, 1563–1570 (2013). Article CAS PubMed Google Scholar Liu, E. et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistenc...
B cell aplasia is used as a surrogate for CAR19 T cell activity. As an exploratory analysis, we measured the frequencies of CD19-positive B cells in the PB of patients after CAR-NK cell treatment. At the time of enrollment, the majority of patients (31/37) had B cell lymphopenia (B...
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients J Clin Invest, 126 (2016), pp. 2123-2138 View in ScopusGoogle Scholar 3 RA Gardner, O Finney, C Annesley, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose ...
2024 Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia Laurent Phely, MD1; Luca Hensen, PhD1; Christoph Faul, MD1; et al Christer Alexander Ruff, MD2; Dina Schneider, PhD3; Wolfgang Andreas Bethge, MD1; Claudia Lengerke, MD1 Author Affiliations Article Informati...
edited using CRISPR/Cas9 were confirmed to be equivalent to that of normal CAR-T19 cells, both in vitro and in an animal model. Next, a clinical trial was conducted to verify the safety and efficacy of an "off-the-shelf" allogeneic CAR-T cell product targeting CD19 in patients with R/...
the BCMA-targeted allogeneic CAR-T cell therapy for the treatment of multiple myeloma and plasma cell leukemia and the CD19/CD20 dual-targeted allogeneic CAR-T cell therapy for the treatment of B-cell malignancies. An investment fund manag...
Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. Br J Haematol. 2017;179:598–605. Article CAS Pub...
The above-mentioned CAR-NK cell is an example of genetic manipulations beyond that of CD16 with the goal of increasing tumor targeting. CARs are of interest because of the success they have shown in the T cell field [27] and the promise they are starting to show in NK cell immunotherapy...
(GVHD), allogeneic rejection, potential genotoxic stress associated with gene editing, and infection risk due to over-immunosuppression limit the broader clinical application of current allogeneic CAR-T cell products.6In this study, we demonstrated that an allogeneic CD19-targeted CAR-T cell therapy ...